Search
Stabilin-2
go.drugbank.com/bio_entities/BE0004948TargetHumansAlso acts, in different species, as a primary systemic scavenger receptor for heparin (Hep), chondroitin sulfate (CS), dermatan sulfate (DS), nonglycosaminoglycan (GAG), acetylated low-density lipoprotein … Counter receptor which plays an important role in lymphocyte recruitment in the hepatic vasculature.
Synonyms: Hyaluronan receptor for endocytosisTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … [L41730] TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.[A18804,A19332,A19333,A19334,A19335]
Categories: Compounds used in a research, industrial, or household settingElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma. … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] TTR mutations lead to the formation of misfolded TTR proteins, which form amyloid fibrils that deposit in different types of tissues. … [L42085] Another siRNA indicated for the treatment of polyneuropathy associated with hereditary ATTR is [patisiran].[A249010] Vutrisiran was approved by the FDA in June 2022.
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalIt was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. … The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL.
Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamideOlsalazine
go.drugbank.com/drugs/DB01250Approved[A257063] It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. … [A257063] Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151]
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigationalSevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain … [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]
Categories: MATE 2-K InhibitorsFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant … HIV-1 fills a necessary niche for therapeutic options in patients left with few, if any, viable treatments.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseFexinidazole
go.drugbank.com/drugs/DB12265Approved[A237550, A237560] Fexinidazole, which was originally developed in the 1970s/80s by Hoechst AG and subsequently rediscovered through the Drugs for Neglected Diseases Initiative (DNDi) in 2005, is the first … all-oral treatment for first and second stage HAT caused by _T. brucei gambiense_.
Categories: MATE 2-K InhibitorsElamipretide
go.drugbank.com/drugs/DB11981ApprovedInvestigationalFood and Drug Administration (FDA) granted accelerated approval for FORZINITY™ (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. … Elamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction.